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agree that the use of IdeS in patients with strong 
cytotoxic antibodies needs to be approached care-
fully. The high rate of delayed graft function in 
the U.S. cohort is similar to what we see in our 
recipients of deceased donor kidneys. Delayed 
graft function is unlikely to be due to IdeS, since 
it was not seen in the Swedish population, which 
involved donors with low cold ischemia times 
and machine perfusion.
We performed renal biopsies in four patients 
during the first week after transplantation. All the 
biopsy specimens showed mild tubular injury 
with no microvascular inflammation and no 
C4d staining. In addition, no evidence of IgG 
fragments was seen in the glomeruli or tubules. 
Signaling by F(ab′)2 fragments of donor-specific 
antibodies has been described.1 Using an in vitro 
model of neuromyelitis optica in which antibod-
ies to the autoantigen aquaporin-4 (AQP4) were 
cleaved by IdeS, Tradtrantip et al.2 found that 
F(ab′)2 fragments of anti-AQP4 binding to AQP4-
positive cells protected cells from antibody-
dependent cellular and complement-mediated 
cytotoxic effects by intact anti-AQP4 IgG. The 
sample size in our study is too small to stratify 
patients according to the estimated glomerular 
filtration rate on the basis of chronic kidney 
disease status. We agree that larger studies of 
IdeS with the use of protocols to block antibody 
rebound are critical.
Goldstein believes that we have overstated the 
degree to which sensitization impedes the trans-
plantation of kidneys from deceased donors. The 
assertion that sensitized patients undergo trans-
plantation at rates similar to those among non-
sensitized patients is not accurate. Although the 
new kidney allocation system has dramatically 
increased transplantation rates among candi-
dates with a calculated panel-reactive antibody 
level of 100%, a substantial percentage (40 to 
47%) of these candidates underwent transplan-
tation across positive donor-specific antibodies 
and flow-cytometric cross-match barriers after 
completing desensitization.3 The rate of trans-
plantation of a deceased donor kidney among 
candidates with a calculated panel-reactive anti-
body level of 100% increased (from 2.4% to 
13.4%) after the implementation of the kidney 
allocation system. However, recent data show that 
the transplantation rate among these candidates 
has decreased to 9.4%. The transplantation rate 
among candidates with a calculated panel-reactive 
antibody level of 95 to 98% is 3.1%.4 For Euro-
transplant, a suitable donor cannot be found for 
a considerable percentage (approximately 35%) 
of highly HLA-sensitized patients (http://cordis 
. europa . eu/ result/ rcn/ 181463_en . html). In that cir-
cumstance, desensitization is the only option to 
increase transplantation rates.
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Abiraterone in Metastatic Prostate Cancer
To the Editor: Fizazi et al. (July 27 issue)1 report 
on the LATITUDE trial, and in the same issue, 
James et al.2 report on the Systemic Therapy in 
Advancing or Metastatic Prostate Cancer: Evalua-
tion of Drug Efficacy (STAMPEDE) trial. These 
phase 3 trials involving a total of more than 3000 
men with advanced prostate cancer were designed 
after abiraterone was proved to prolong survival 
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among patients with advanced prostate cancer. 
Before these trials, the standard of care for pa-
tients with advanced prostate cancer included se-
quential androgen suppression with various life-
prolonging therapies (e.g., taxanes, abiraterone, 
or enzalutamide).
However, the control regimens in the 
 STAMPEDE and LATITUDE trials were not de-
signed to include the current sequential standard 
of care with life-prolonging crossover treatments; 
these treatments were not specified in the pro-
tocols (available with the full text of the articles 
at NEJM.org). This is critical, since the majority 
of men in the control groups in the STAMPEDE 
and LATITUDE trials died without exposure to 
abiraterone or enzalutamide. Thus, the drugs 
used in these control groups were inconsistent 
with current prevailing standards of care. This 
has implications for the conclusions of the trials 
and raises questions regarding whether or not 
there was a benefit for all trial participants.
Discussions between patients and physicians 
regarding the results of these trials should be 
made in the context of the above considerations. 
Physicians must reflect on the urgent need to 
better define and use surrogate end points so 
that death is not needed to conclude that a regi-
men is active.
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To the Editor: The STAMPEDE and LATITUDE 
trials show that abiraterone improved survival 
substantially among men with metastatic pros-
tate cancer when this drug was added to stan-
dard androgen-deprivation therapy. Abiraterone 
has minimal toxic effects and would benefit such 
men worldwide, but it is available to only a minor-
ity of patients. The monthly price of abiraterone 
at the Food and Drug Administration–approved 
dose of 1000 mg per day (after an overnight fast) 
is approximately $10,000 in the United States; 
this is unaffordable in middle-income and lower-
income countries.
The price of abiraterone bears no relationship 
to the minimal cost of production. Abiraterone 
was developed and first patented at the Institute 
of Cancer Research in the United Kingdom in the 
early 1990s. Janssen markets the drug and has 
an extended patent based on a questionable claim 
for combined administration with prednisone. A 
recent study points to ways to increase the avail-
ability of abiraterone by suggesting that the ad-
ministration of 250 mg per day after consump-
tion of a low-fat meal may be as effective as the 
higher dose (after an overnight fast)1 and that 
full-dose abiraterone is available in India for ap-
proximately $450 per month. Given that the drug 
was developed 25 years ago in an academic center, 
the high price is unacceptable. We recommend 
that oncologists lobby to make abiraterone avail-
able to all patients who might benefit, just as ret-
roviral drugs are available for patients with AIDS.
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Toronto, ON, Canada 
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To the Editor: Fizazi et al. suggest that abi-
raterone plus prednisone in combination with 
standard androgen-deprivation therapy signifi-
cantly improved outcomes among patients with 
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high-risk metastatic prostate cancer who had not 
received hormone therapy. At a median follow-up 
of 30.4 months, they confirmed the significant 
effect of abiraterone plus prednisone in combi-
nation with androgen-deprivation therapy. The 
median rate of overall survival was not reached 
among patients in the abiraterone group as com-
pared with 34.7 months among those in the pla-
cebo group (hazard ratio for death, 0.62; 95% 
confidence interval, 0.51 to 0.76; P<0.001). The 
STAMPEDE trial showed similar results.
The Chemohormonal Therapy Versus Andro-
gen Ablation Randomized Trial for Extensive 
Disease in Prostate Cancer (CHAARTED) showed 
a similar outcome with the use of six cycles of 
docetaxel in combination with androgen-depri-
vation therapy, and docetaxel is very affordable 
as compared with abiraterone plus androgen-
deprivation therapy.1 Comparative and cost-effec-
tive studies should be conducted to define the 
best systemic therapy for patients with metastatic 
prostate cancer who have not received hormone 
therapy.
Nabil Ismaili, M.D. 
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Dr. James and colleagues reply: In response 
to de Bono and colleagues, who ask about the 
development of a clinically meaningful early sur-
rogate end point in patients with prostate cancer 
who have not received hormone therapy: this has 
been an unmet need. The Intermediate Clinical 
Endpoints in Cancer of the Prostate (ICECaP) col-
laboration has addressed this issue in patients 
with nonmetastatic disease1; the ICECaP collabo-
ration is now expanding to include men with 
metastatic (M1) disease.
They also ask whether survival gains observed 
in the STAMPEDE and LATITUDE trials were 
boosted by inadequate access to abiraterone and 
enzalutamide on relapse. STAMPEDE was an 
open-label trial in which treatments in patients 
with disease that had relapsed were determined 
by the responsible clinician. During the trial, 
abiraterone and enzalutamide were widely avail-
able, as were docetaxel, cabazitaxel, and radium- 
223. These “life-prolonging” agents have similar 
effects on survival among patients with relapsed 
prostate cancer; there is no agreed-upon single 
standard of care.2 Among the patients in the 
control group (i.e., patients who received andro-
gen-deprivation therapy alone) in the STAMPEDE 
trial who died of prostate cancer, 74% explicitly 
reported that they had received one or more of 
these five therapies. Data on second-, third-, and 
fourth-line treatments are increasingly difficult to 
collect and thus are underreported, so true rates 
of exposure to these therapies will be higher 
than 74%. The double-blind, placebo-controlled 
LATITUDE trial produced strikingly similar out-
comes with different patterns of care after re-
lapse; this suggests that differing patterns of 
care after relapse between the STAMPEDE and 
LATITUDE trials were not important drivers of 
differences in survival.
Furthermore, among patients with relapsed 
disease who had not received previous chemo-
therapy and who received abiraterone in the 
COU-AA-302 study, the median progression-free 
survival was approximately 16.5 months,3 and 
the median time to treatment failure in the con-
trol group of patients with M1 disease in the 
STAMPEDE trial was approximately 11 months, 
so the estimated time to abiraterone failure was 
27.5 months. In comparison, the median failure-
free survival with first-line abiraterone among pa-
tients with metastatic disease in the STAMPEDE 
trial was approximately 54 months; this sug-
gests that a crossover strategy would not have 
yielded a different outcome.
In response to Tannock: drug development is 
more than chemical synthesis. Much value lies in 
the intellectual property in clinical development, 
which is costly and lengthy. Drug development 
depends on investment generating sufficient re-
turn for investors and inventors. The U.S. patent 
extension is sub judice. Drug pricing is complex, 
and the U.S. headline price is far higher than the 
price paid elsewhere. Affordability is thus a func-
tion of the need for health care systems and 
payers to collaborate with drug developers to 
ensure an active, continual pipeline while ensur-
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ing value for all. As highlighted by de Bono et al., 
more robust, surrogate end points and new trial 
designs (as used in the STAMPEDE trial) can 
help speed trial completion and thereby reduce 
costs for all concerned.
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Drs. Fizazi and Chi reply: The phase 3 LATITUDE 
trial showed an improved outcome, including 
prolonged survival, when abiraterone and predni-
sone were combined with androgen-deprivation 
therapy in men with newly diagnosed metastatic 
prostate cancer.
In their letter, de Bono and colleagues ques-
tion the control regimen used in the LATITUDE 
trial, which consisted of androgen-deprivation 
therapy alone, followed in cases of cancer pro-
gression by drugs recommended for castration-
resistant prostate cancer and used according to 
the investigators’ decision. However, although six 
drugs have been shown to improve survival 
among men with castration-resistant prostate 
cancer, no clear guidance for their use is avail-
able.1 Moreover, many physicians may prefer the 
use of a taxane rather than a drug targeted to 
the androgen-receptor axis such as abiraterone or 
enzalutamide at the onset of progression in men 
in whom castration-resistant prostate cancer may 
quickly develop.2 Thus, a mandatory crossover to 
abiraterone in our trial may have been challeng-
ing and perhaps in some cases clinically inade-
quate. Finally, the LATITUDE trial is not an ex-
ception among its kind: data are limited from 
randomized trials in advanced prostate cancer 
that have used a systematic crossover of the ex-
perimental drug in the control group.3,4 Of note, 
in the LATITUDE trial, more patients in the 
placebo group than in the abiraterone group 
received at least one life-prolonging therapy after 
they had disease progression (246 vs. 125 patients 
[41% vs. 21%], respectively). This suggests that 
the survival benefit observed in the experimental 
group was truly related to the initial use of abi-
raterone, not to active drugs used after disease 
progression.
Tannock, as well as Ismaili and Guessous, 
emphasize the financial cost of abiraterone, and 
they respectively advocate for a reduction of price 
or comparison with docetaxel (a generic drug). 
We agree that drug pricing should generally be 
adapted so that most patients can benefit world-
wide, and this opinion is not restricted specifi-
cally to abiraterone. Regarding the comparison 
with docetaxel, although no direct comparison 
with a randomized trial is available, indirect com-
parisons with the use of Bayesian network analy-
sis are ongoing, and we agree that cost-effec-
tiveness studies will be important to perform. 
Consideration should be given to differences 
between the two regimens (i.e., androgen-depriva-
tion therapy plus docetaxel and androgen-depri-
vation therapy plus abiraterone) with respect to 
toxic effects and the potential effect on quality 
of life. An important question will be whether 
abiraterone also improves outcomes in men receiv-
ing androgen-deprivation therapy plus docetaxel as 
their standard of care, and this is currently be-
ing tested in the PEACE1 trial (ClinicalTrials.gov 
number, NCT01957436).
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Migraine
To the Editor: In the discussion of preventive 
therapy for migraines, Charles (Aug. 10 issue)1 
did not include aspirin as an effective option. 
Several large, randomized, double-blind, placebo-
controlled trials, including the Physicians’ Health 
Study,2 have reported that the regular use of low-
dose aspirin is effective in migraine prevention. 
A recent systematic review of studies on migraine 
prophylaxis with aspirin confirmed that regular 
use of low-dose aspirin can reduce the frequency 
of migraine.3 A comparison study of aspirin and 
metoprolol for migraine prevention reported re-
ductions in migraine frequency in both groups, 
with the metoprolol group having a greater re-
sponse (42.5%, vs. 29.6% in the aspirin group) 
but also having more medication-related side ef-
fects than the aspirin group.4 Another recent re-
view of drugs for migraine also neglected to dis-
cuss the effectiveness of aspirin in prophylaxis.5 
Given its documented effectiveness, low side-effect 
profile (especially in the young), and low cost, 
aspirin should not be overlooked as a useful 
means of migraine prevention.
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The author replies: Langland points to studies 
indicating the potential efficacy of acetylsalicylic 
acid (aspirin) as preventive therapy for migraine. 
Although these studies do report that acetylsali-
cylic acid, at a dose of 325 mg, is of modest benefit 
for migraine prevention, the data are not suffi-
cient to warrant the highest level of recommen-
dation in any of the major guidelines.1-3 Nonethe-
less, it is reasonable to consider acetylsalicylic 
acid as a preventive approach to migraine, particu-
larly in patients who have other conditions for 
which daily acetylsalicylic acid may be beneficial. 
A number of other treatments fall into this cate-
gory — that is, those for which there is some 
evidence of efficacy but for which there is neither 
sufficient evidence nor expert consensus to war-
rant the highest level of recommendation. These 
treatments include other nonsteroidal antiinflam-
matory medications,1 f lunarizine, gabapentin, 
venlafaxine, verapamil,2-4 and behavioral thera-
pies,5 among multiple others. As is the case with 
acetylsalicylic acid, these treatments may be con-
sidered as migraine-preventive therapies in pa-
tients with other coexisting conditions for which 
the treatments are indicated or in patients for 
whom first-line approaches are ineffective or have 
unacceptable side effects.
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